Abstract: A nucleic acid medicine for managing a disease or disorder related to unwanted gene expression. A technique for efficiently regulating gene expression in a cell using a relatively short oligonucleotide, by establishing a method for designing a nucleic acid medicine, that includes performing structural analysis based on sequence information of a target RNA sequence as an object for gene expression regulation, calculating the probability of existence of each structure from the results of the structural analysis and the energy of each structure, and calculating the existence probability in unified fashion of an endogenous stem-loop substructure, thereby specifying a more favorable endogenous stem-loop substructure. This technique can theoretically be applied to regulation expression of any gene, and is useful for treatment or prevention of various diseases and disorders.

Abstract: There is provided a heptamer-type small guide nucleic acid that comprises any of the 7-base sequences of SEQ ID NOS: 1 to 15, and induces apoptosis of human leukemia cells. A leukemia therapeutic agent containing the heptamer-type small guide nucleic acid as an active ingredient is also provided. The novel heptamer-type sg nucleic acid can induce apoptosis of human leukemia cells.

Abstract: There is provided a heptamer-type small guide nucleic acid that comprises any of the 7-base sequences of SEQ ID NOS: 1 to 15, and induces apoptosis of human leukemia cells. A leukemia therapeutic agent containing the heptamer-type small guide nucleic acid as an active ingredient is also provided. The novel heptamer-type sg nucleic acid can induce apoptosis of human leukemia cells.

Abstract: As a molecular material for synthesizing a protein-encoding polynucleotide via reverse translation from the protein, a reverse translation-mediating oligonucleotide having the following properties (a) to (d) is provided: (a) containing a nucleotide sequence “nnn” encoding an amino acid residue “Xaa”; (b) the nucleotide sequence “nnn” being separable; (c) containing a nucleotide sequence binding to the amino acid residue “Xaa”; and (d) not containing any nucleotide sequence binding to an amino acid residue other than the amino acid residue “Xaa”. Also, a method of synthesizing a polynucleotide encoding the amino acid sequence of the primitive protein via a reverse translation reaction with the above oligonucleotide is provided.